Status:
RECRUITING
Functionality of Albumin in the Context of Hemodialysis
Lead Sponsor:
Universität Duisburg-Essen
Conditions:
Albumin
Dialysis
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Hemodialysis treatment enables patients with end-stage chronic kidney disease to survive. At the same time, however, this treatment also increases cardiovascular mortality, in particular due to a chro...
Eligibility Criteria
Inclusion
- 18 years or older at least 3 month of hemodialysis treatment (3x/week) with constant dialysis treatment regimen
Exclusion
- Age ≤ 18 years
- Less than three months of regular (3x/week) hemodialysis treatments or less than 3 treatments/week
- Acute or chronic liver disease (Child stage A or higher or fulfillment of the of the Kings College criteria)
- Infusion of commercial human albumin (e.g. in the context of ascites drainage) in the last three months prior to study inclusion
- Acute or severe chronic infections
- Acute tumor disease
Key Trial Info
Start Date :
August 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2025
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT06561191
Start Date
August 1 2024
End Date
December 1 2025
Last Update
August 19 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital Essen
Essen, Germany, 45147